WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma Patients were randomly assigned to receive I-DXd 8 ...

A phase 3 trial of Spine BioPharma’s chronic low back pain candidate has missed its primary endpoint. But, with the biotech pinning the failure on a “very high sham control response,” management plans ...